Table 1. Genomic alterations described in high-grade serous ovarian cancer (HGSOC, accounting for 75% of epithelial ovarian cancers)
From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
Alteration type | Selected genomic alterations and frequency in HGSOC |
|---|---|
Defective homologous recombination (occurs in roughly 50% of HGSOC) | Germline BRCA mutation (10%–15%) |
Somatic BRCA mutation (5%) | |
BRCA promoter hypermethylation (10%–15%) | |
EMSY amplification (5%–15%) | |
RAD51 loss (<5%) | |
ATM/ATR mutation (3%) | |
Fanconi gene mutations (5%) | |
Oncogenic amplifications | MAPK (25%) |
PIK3CA (20%) | |
CCNE (20%) | |
KRAS (11%) | |
RICTOR (6%) | |
AKT1, AKT2, or AKT3 (15%) | |
RAPTOR (4%) | |
ERBB3 (4%) | |
ERBB2 (3%) | |
IGF-1R (3%)… | |
Oncogenic loss | PTEN (7%) |
Oncogenic mutations | EGFR (4%–9%) |
PIK3CA (3%) | |
PDGFR (4%) | |
KIT (3%) | |
ERBB2 (1%)… |